GlassScriptPhysician profile
William L Johnson
NPI 1669476495
$6,687.30
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $767 · 2021: $1,664 · 2022: $2,375 · 2023: $1,164 · 2024: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989 · Honoraria: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.21 |
| Honoraria | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,392.44 | 2019-2023 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,068.00 | 2019-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Aimmune Therapeutics, INC. | $629.84 | 2020-2024 | |
| Kaleo, INC. | $442.28 | 2019-2023 | Auvi-Q |
| Optinose US, INC. | $369.67 | 2019-2023 | |
| Genzyme Corporation | $352.59 | 2020-2023 | |
| Pfizer INC. | $324.57 | 2019-2023 | |
| Csl Behring | $311.47 | 2021-2023 | Hizentra, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $269.78 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $239.62 | 2020-2022 | |
| Genentech USA, INC. | $169.64 | 2019-2023 | Xolair |
| Novartis Pharmaceuticals Corporation | $139.84 | 2020-2023 | |
| Grifols USA, LLC | $123.46 | 2020-2023 | Xembify |
| Bio Products Laboratory USA, INC. | $121.28 | 2022-2023 | Gammaplex, Coagadex |
| Regeneron Healthcare Solutions, INC. | $120.80 | 2019-2023 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $118.73 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.54 | 2019-2023 | Spiriva Respimat |
| Amgen INC. | $109.76 | 2021-2023 | Tezspire |
| Adma Biomanufacturing LLC | $70.81 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $34.76 | 2021-2022 | |
| Horizon Therapeutics Plc | $31.25 | 2020-2022 | |
| Incyte Corporation | $29.67 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.17 | 2019 | |
| Alk-Abello, INC | $19.54 | 2022 | |
| Merck Sharp & Dohme LLC | $17.32 | 2021 | |
| Stryker Corporation | $15.21 | 2021 | |
| Hikma Pharmaceuticals USA | $15.20 | 2023 | Ryaltris |
| Sunovion Pharmaceuticals INC. | $13.06 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.